CDRI-97/78 is an antimalarial agent. CDRI-97/78 has phototoxicity and can induce cell apoptosis and G2/M phase arrest. CDRI-97/78 can be used for the research of infection.

BAL-0019764 is an iron carrier monocyclic β-lactam with broad-spectrum β-lactase inhibition ability. BAL-0019764 has inhibitory activity against various Gram negative bacteria. BAL-0019764 is commonly used in the study of bacterial infections.

(±)-PM 92131 is a non-nucleoside HIV-1 inhibitor. (±)-PM 92131 has an anti-HIV-1 activity with IC50s of 45.7 and 53.8 μM for HIV-1 RF strain in XTT cytoprotection and syncytium-forming assay, respectively. (±)-PM 92131 can be used for HIV infections research.

HMR-3787 is a 2-fluoroketolide and bactericide. HMR 3787 is bactericidal against 12 H. influenzae strains.

Asuptegravir (Compound 1) is an inhibitor of HIV integrase activity. Asuptegravir inhibits HIV in HEK293T cells (EC50 = 1.08 nM). Asuptegravir can be studied in anti-AIDs/HIV research.

CMLD009688 is a cationic amphiphilic antifungal agent. CMLD009688 selectively inhibits plant pathogenic fungi such as Fusarium graminearum. CMLD009688 interacts with biological membranes, perturbing vacuolar and mitochondrial membrane structures to induce fungal cell death. CMLD009688 is promising for research of plant fungal diseases (e.g., wheat head blight, gray mold).

BAL-19403 is a new type of macrolide antibiotic. BAL-19403 exhibits excellent activity against Propionibacterium acnes, particularly effective against erythromycin and clindamycin resistant strains. BAL-19403’s main functions are antibacterial and anti-inflammatory activity. BAL-19403 can be used for research on acne.

(+)-PM 92131 is the active enantiomer of (±)-PM 92131. (+)-PM 92131 is a non-nucleoside HIV-1 inhibitor. (+)-PM 92131 has an anti-HIV-1 activity with EC50s of 0.8 and 0.6 μM for HIV-1 RF strain in XTT cytoprotection and syncytium-forming assay, respectively. (+)-PM 92131 can be used for HIV infections research.

RAM1147 is a farnesyl pyrophosphate synthase (FPPS) inhibitor. RAM1147 disrupts protein isoprenylation, inhibiting tumor cell proliferation. RAM1147 is promising for research of cancers (e.g., myeloma, breast cancer) and bone metabolism disorders (e.g., osteoporosis).

MRSA antibiotic 3 (Compound C8) is a small-molecule antibiotic active against Methicillin)-resistant Staphylococcus aureus (MRSA), showing a MIC of 0.5 μg/mL against the standard S. aureus strain (ATCC 29213). MRSA antibiotic 3 potently inhibits the ATPase activity of S. aureus DNA gyrase with an IC50 of 0.32 μM. MRSA antibiotic 3 exhibits strong inhibitory activity against five clinical MRSA isolates, with MIC values ranging from 0.5 to 1 μg/mL. MRSA antibiotic 3 demonstrates negligible cytotoxicity at effective antibacterial concentrations and causes no hemolysis in erythrocytes even at extremely high concentrations. MRSA antibiotic 3 shows significant protective effects in both Galleria mellonella infection and murine sepsis models.

(Z)-Heptaprenyl-MPDA ((Z)-Heptaprenyl phosphate) diammonium is the (Z)-isomer of Heptaprenyl-MPDA. Heptaprenyl-MPDA (Heptaprenyl phosphate) is a short-chain homolog of undecaprenyl phosphate, is an endogenous substrate of Phospho-MurNAc-pentapeptide translocase (MraY). Heptaprenyl-MPDA can be used for bacterial infections research.

Δ²-Avermectin B₁ₐ (Compound 3) is an antiparasitic agent targeting glutamate-gated chloride channels (GluCls) in the neuromuscular system of invertebrates. Δ²-Avermectin B₁ₐ enhances chloride ion influx, leading to hyperpolarization of the neuromuscular cell membrane, inhibition of neural signal transmission, and ultimately paralysis and death of parasites. Δ²-Avermectin B₁ₐ is promising for research of agricultural pests.

(rac)-TBAJ-5307 is the racemate of TBAJ-5307. TBAJ-5307 is a broad spectrum anti-non-tuberculous mycobacteria inhibitor that can target the FO-domain of the engine and preventing rotation and proton-translocation.

Zintevir is an antisense oligonucleotide that targets HIV-1 integrase.

Zintevir sodium is an antisense oligonucleotide that targets HIV-1 integrase.

Tomligisiran is a siRNA in JNJ-3989 (JNJ-73763989). JNJ-3989 is comprised of 2 siRNAs (Daplusiran and Tomligisiran), that target hepatitis B virus (HBV) mRNAs for degradation, thereby inhibiting HBV replication.

Tomligisiran sodium is a siRNA in JNJ-3989 (JNJ-73763989). JNJ-3989 is comprised of 2 siRNAs (Daplusiran and Tomligisiran), that target hepatitis B virus (HBV) mRNAs for degradation, thereby inhibiting HBV replication.

SARSi-4 sodium is a siRNA that markedly inhibited the replication of SARS-associated coronavirus (SCoV).

Peginterferon alfa-2b (PegIFN a-2b) is an immunomodulator. Peginterferon alfa-2b is a recombinant alfa-2b interferon covalently linked PEG. Peginterferon alfa-2b in decreasing viral DNA in HIV. Peginterferon alfa-2b can be used in research of melanoma and hepatitis C.

Ozisiran, a siRNA, is a hepatitis B virus (HBV) RNA transcript reducer with antiviral activity.

Ozisiran sodium, a siRNA, is a hepatitis B virus (HBV) RNA transcript reducer with antiviral activity.

S 3578 (sulfate) is a broad-spectrum antibacterial agent, particularly effective against methicillin-resistant Staphylococcus aureus (MRSA) (MIC = 0.78-3.13 μg/mL) and Pseudomonas aeruginosa (MIC = 1.56-6.25 μg/mL). S 3578 (sulfate) can be used in the research of infectious conditions.

BO 1341 is a PBPs inhibitor and an antipseudomonal semisynthetic cephalosporin. BO 1341 exhibits antibacterial activity against most Gram-negative bacteria, such as Pseudomonas aeruginosa (MIC90: 1.56 μg/mL), Pseudomonas maltophilia (MIC50: 1.56 μg/mL), and Acinetobacter calcoaceticus (MIC90: 3.13 μg/mL) . BO 1341 can be used in the research of infectious diseases.

DQ 2556 is a semi-synthetic cephalosporin antibiotic. DQ-2556 exhibits significant activity against both Gram-positive and Gram-negative bacteria, particularly Gram-positive bacteria and Enterobacteriaceae infections. DQ 2556 exerts its bactericidal effect by interfering with cell division. DQ-2556 has a strong affinity for the penicillin-binding proteins (PBPs) of Escherichia coli: PBP1A/1B (IC₅₀ = 0.57-0.73 μg/mL) and PBP3 (IC₅₀ = 0.088 μg/mL). DQ-2556 demonstrates significant in vivo protective effects. DQ-2556 can be used in the development of injectable cephalosporins.

ME-1036 (CP-5609) is a carbapenem antibiotic. ME-1036 against resistant Gram-positive organisms, including Methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococci (VRE), and ESBL-producing E. coli and K. pneumoniae but is not effective against P. aeruginosa.

(-)-Luteoskyrin has a wide range of antibacterial activity, such as against malaria (with an IC50 of 0.51 μg/mL), tuberculosis (MIC of 6.25 μg/mL), and it also shows antibacterial effects (with MIC for Gram-positive bacteria ranging from 0.39 to 1.56 μg/mL, and for Gram-negative bacteria from 3.13 to 12.50 μg/mL), as well as antifungal activity (with MIC against plant pathogens ranging from 3.13 to 50μg/mL). (-)-Luteoskyrin exhibits cytotoxicity against NCI-H187 cells, with an IC50 range of 0.16–17.99 μg/mL.

KKL-55 is a specific small molecule inhibitor of bacterial trans-translation by binding to longation factor thermo-unstable (EF-Tu, Kd=2 uM), inhibits binding between EF-Tu and tmRNA but not between EF-Tu and tRNA, has broad-spectrum antibiotic activity.

MU-UNMC-2 is a potential small-molecule inhibitor of S-RBD and ACE-2 interaction, shows antiviral activity against SARS-CoV-2 with IC50 of 1.72 uM in human bronchial epithelial cells.

VV261 is an orally active Influenza Virus inhibitor. VV261 has demonstrated activity against severe febrile thrombocytopenia syndrome virus (SFTSV) and lymphocytic choriomeningitis virus (LCMV) (EC50: 0.89 and 0.15, respectively).

MRV03-070 is an inhibitor of colibactin-activating peptidase ClbP with an IC50 value of 69 nM, acts like biosynthetic precursor precolibactin.